Citadel Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $415K | Sell |
118,276
-105,693
| -47% | -$433K | ﹤0.01% | 9743 |
|
|
2025
Q4 | $755K | Sell |
223,969
-420,077
| -65% | -$1.09M | ﹤0.01% | 8041 |
|
|
2025
Q3 | $844K | Buy |
644,046
+334,774
| +108% | +$346K | ﹤0.01% | 7910 |
|
|
2025
Q2 | $222K | Sell |
309,272
-631,276
| -67% | -$496K | ﹤0.01% | 10464 |
|
|
2025
Q1 | $1.38M | Buy |
940,548
+380,084
| +68% | +$905K | ﹤0.01% | 6248 |
|
|
2024
Q4 | $2.48M | Sell |
560,464
-136,962
| -20% | -$556K | ﹤0.01% | 5189 |
|
|
2024
Q3 | $2.87M | Buy |
697,426
+287,893
| +70% | +$1.55M | ﹤0.01% | 4860 |
|
|
2024
Q2 | $2.67M | Sell |
409,533
-423,741
| -51% | -$3M | ﹤0.01% | 4784 |
|
|
2024
Q1 | $7.26M | Buy |
833,274
+337,803
| +68% | +$4.1M | ﹤0.01% | 3394 |
|
|
2023
Q4 | $5.67M | Buy |
495,471
+381,454
| +335% | +$3.77M | ﹤0.01% | 3608 |
|
|
2023
Q3 | $1.1M | Sell |
114,017
-8,270
| -7% | -$81.1K | ﹤0.01% | 6371 |
|
|
2023
Q2 | $1.3M | Sell |
122,287
-254,574
| -68% | -$2.74M | ﹤0.01% | 5931 |
|
|
2023
Q1 | $3.96M | Buy |
376,861
+305,687
| +429% | +$3.42M | ﹤0.01% | 4176 |
|
|
2022
Q4 | $882K | Buy |
71,174
+52,655
| +284% | +$597K | ﹤0.01% | 7047 |
|
|
2022
Q3 | $192K | Buy |
+18,519
| New | +$210K | ﹤0.01% | 10444 |
|
|
2022
Q2 | – | Sell |
-836,648
| Closed | -$10.5M | – | 13473 |
|
|
2022
Q1 | $10.5M | Buy |
836,648
+484,521
| +138% | +$5.55M | ﹤0.01% | 2860 |
|
|
2021
Q4 | $4.11M | Buy |
352,127
+260,393
| +284% | +$3.19M | ﹤0.01% | 4688 |
|
|
2021
Q3 | $1.2M | Sell |
91,734
-79,701
| -46% | -$1.03M | ﹤0.01% | 7680 |
|
|
2021
Q2 | $2.21M | Sell |
171,435
-114,339
| -40% | -$1.31M | ﹤0.01% | 6344 |
|
|
2021
Q1 | $3.19M | Sell |
285,774
-67,769
| -19% | -$716K | ﹤0.01% | 5287 |
|
|
2020
Q4 | $4.03M | Sell |
353,543
-284,403
| -45% | -$3.11M | ﹤0.01% | 4053 |
|
|
2020
Q3 | $5.74M | Sell |
637,946
-47,801
| -7% | -$475K | ﹤0.01% | 2959 |
|
|
2020
Q2 | $7.08M | Sell |
685,747
-52,880
| -7% | -$541K | ﹤0.01% | 2620 |
|
|
2020
Q1 | $7.45M | Sell |
738,627
-573,538
| -44% | -$6.74M | ﹤0.01% | 2209 |
|
|
2019
Q4 | $17.5M | Sell |
1,312,165
-1,266,004
| -49% | -$14M | 0.01% | 1611 |
|
|
2019
Q3 | $22.1M | Sell |
2,578,169
-1,573,393
| -38% | -$15.3M | 0.01% | 1376 |
|
|
2019
Q2 | $45.4M | Buy |
4,151,562
+171,079
| +4% | +$1.92M | 0.02% | 785 |
|
|
2019
Q1 | $45.1M | Buy |
3,980,483
+2,191,650
| +123% | +$24.5M | 0.02% | 743 |
|
|
2018
Q4 | $15.5M | Buy |
1,788,833
+1,247,315
| +230% | +$14.3M | 0.01% | 1437 |
|
|
2018
Q3 | $8.37M | Sell |
541,518
-65,414
| -11% | -$1.03M | ﹤0.01% | 2339 |
|
|
2018
Q2 | $9.72M | Buy |
606,932
+314,169
| +107% | +$4.65M | ﹤0.01% | 1965 |
|
|
2018
Q1 | $3.78M | Buy |
+292,763
| New | +$3.65M | ﹤0.01% | 2816 |
|
|
2016
Q4 | – | Sell |
-267,452
| Closed | -$3.56M | – | 7542 |
|
|
2016
Q3 | $3.56M | Buy |
267,452
+255,280
| +2,097% | +$2.98M | ﹤0.01% | 2322 |
|
|
2016
Q2 | $133K | Buy |
+12,172
| New | +$119K | ﹤0.01% | 6068 |
|
|
2015
Q4 | – | Sell |
-388,627
| Closed | -$3.76M | – | 8933 |
|
|
2015
Q3 | $3.39M | Buy |
+388,627
| New | +$3.63M | ﹤0.01% | 2327 |
|
|
2015
Q2 | – | Sell |
-357,701
| Closed | -$4.16M | – | 8889 |
|
|
2015
Q1 | $4.79M | Buy |
357,701
+294,667
| +467% | +$3.87M | ﹤0.01% | 2075 |
|
|
2014
Q4 | $809K | Sell |
63,034
-203,099
| -76% | -$2.32M | ﹤0.01% | 4034 |
|
|
2014
Q3 | $2.89M | Buy |
266,133
+230,301
| +643% | +$2.64M | ﹤0.01% | 2488 |
|
|
2014
Q2 | $460K | Sell |
35,832
-41,939
| -54% | -$456K | ﹤0.01% | 4502 |
|
|
2014
Q1 | $803K | Sell |
77,771
-361,953
| -82% | -$4.07M | ﹤0.01% | 3705 |
|
|
2013
Q4 | $4.28M | Buy |
439,724
+291,814
| +197% | +$2.62M | 0.01% | 1822 |
|
|
2013
Q3 | $1.47M | Sell |
147,910
-1,717
| -1% | -$16.8K | ﹤0.01% | 2689 |
|
|
2013
Q2 | $1.25M | Buy |
+149,627
| New | +$1.81M | ﹤0.01% | 2961 |
|
Other funds holding IRWD
AC
SCM
VPM
VCM
Citadel Advisors's IRWD Position: Q1 2026 in Review
Citadel Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 47% in Q1 2026, selling an estimated $433K and leaving 118,276 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #9743.
Citadel Advisors first reported a position in IRWD in Q2 2013 and has held it in 43 quarters since. The position peaked at $45.4M in Q2 2019. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.
- Citadel Advisors held 118,276 shares of Ironwood Pharmaceuticals worth $415K as of Q1 2026.
- Citadel Advisors sold 105,693 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $433K.
- Ironwood Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9743 holding.
- Citadel Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Citadel Advisors's Ironwood Pharmaceuticals position peaked at $45.4M in Q2 2019.
- 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.